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Background: Far infra-red (IFR) therapy was shown to exert beneficial effects in cardiovascular system, but effects
of IFR on endothelial progenitor cell (EPC) and EPC-related vasculogenesis remain unclear. We hypothesized that
IFR radiation can restore blood flow recovery in ischemic hindlimb in diabetic mice by enhancement of EPCs
functions and homing process.
Materials and methods: Starting at 4 weeks after the onset of diabetes, unilateral hindlimb ischemia was induced
in streptozotocine (STZ)-induced diabetic mice, which were divided into control and IFR therapy groups (n = 6 per
group). The latter mice were placed in an IFR dry sauna at 34°C for 30 min once per day for 5 weeks.
Results: Doppler perfusion imaging demonstrated that the ischemic limb/normal side blood perfusion ratio in the
thermal therapy group was significantly increased beyond that in controls, and significantly greater capillary density
was seen in the IFR therapy group. Flow cytometry analysis showed impaired EPCs (Sca-1+/Flk-1+) mobilization after
ischemia surgery in diabetic mice with or without IFR therapy (n = 6 per group). However, as compared to those in
the control group, bone marrow-derived EPCs differentiated into endothelial cells defined as GFP+/CD31+
double-positive cells were significantly increased in ischemic tissue around the vessels in diabetic mice that
received IFR radiation. In in-vitro studies, cultured EPCs treated with IFR radiation markedly augmented high
glucose-impaired EPC functions, inhibited high glucose-induced EPC senescence and reduced H2O2 production.
Nude mice received human EPCs treated with IFR in high glucose medium showed a significant improvement
in blood flow recovery in ischemic limb compared to those without IFR therapy. IFR therapy promoted blood
flow recovery and new vessel formation in STZ-induced diabetic mice.
Conclusions: Administration of IFR therapy promoted collateral flow recovery and new vessel formation in
STZ-induced diabetic mice, and these beneficial effects may derive from enhancement of EPC functions and
homing process.
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Angiogenesis, defined as sprouting of blood vessels from
preexisting vascular structures, is a physiological re-
sponse to ischemia but often fails to produce sufficient
collateral flow to rescue ischemic organ [1]. In animal
models of ischemia, increasing evidence indicates that
administration of angiogenic growth factors, either
through recombinant protein or by gene transfer, can in-
crease nutrients perfusion through neovascularization
and reduce ischemia-related organ damage [2]. However,
there is clinical evidence that some patients, unlike
healthy experimental animals, fail to develop collateral
circulation after tissue ischemia and appear to be refrac-
tory to administration of exogenous growth factors [3].
Patients with diabetes are related to endothelial dysfunc-
tion and have diminished ability for collateral vessel for-
mation in response to ischemia in the heart and
peripheral tissues [4-6].
Convincing evidence suggests that neovascularization
in adults is not solely the result of proliferation of local
endothelial cells (angiogenesis), but also involves bone
marrow-derived circulating endothelial progenitor cells
(EPCs) for the processes of vasculogenesis [7]. However,
patients with cardiovascular risk factors were shown to
have decreased numbers and functions of circulating
EPCs [8]. Our recent study also demonstrated that
long-term exposure to high glucose may enhance cellu-
lar senescence and decrease cell numbers and
functional competencies of EPCs via nitric oxide (NO)-
related mechanisms [9]. Recent evidence showed that
the circulating EPCs levels and arterial stiffness were
closely related to their glycemic control in patients with
type 2 diabetes mellitus (DM) [10]. These findings pro-
vide a rationale for potential therapeutic targets on
hyperglycemia-related vascular complications in diabetic
patients. Far infrared (IFR) radiation is an invisible elec-
tromagnetic wave with a characteristic wavelength be-
tween 5.6 and 1000 μm that can be perceived as heat
by thermo-receptors in the skin [11,12]. Recent studies
indicate that IFR therapy exerts beneficial effects in the
cardiovascular system. IFR radiation improves ventricu-
lar arrhythmias and endothelial function in patients
with heart disease, and enhances access flow and pa-
tency of arteriovenous fistulas in hemodialysis patients
[13-15]. In addition, IFR therapy promotes microvascu-
lar blood flow and angiogenesis in various animal mod-
els [16,17]. Although clinical studies have indicated that
IFR radiation can exert beneficial effects in the cardio-
vascular system, the multi-faceted effects of IFR therapy
on circulating EPCs and diabetes remain unclear.
Therefore, we hypothesized that IFR radiation can im-
prove blood flow recovery after tissue ischemia in dia-
betic mice and improve functional capacities of EPCs
by increasing NO bioavailability.Materials and methods
Animals
Mice at 6–8 weeks old were purchased from the Na-
tional Laboratory Animal Center, Taiwan (FVB mice).
Experimental diabetes was induced in FVB mice by
daily intraperitoneal injections of streptozotocin (STZ)
in citrate buffer (40 mg/kg) for 5 days for the type 1
diabetic model [18]. Mice were considered diabetic only
if they developed glycemia >250 mg/dl and overt glyco-
suria at 14 days after the first STZ injection. Persist-
ence of diabetes was determined at the end of the
study. All mice were kept in microisolator cages on a
12-h day/night cycle. The investigation conforms with
the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication 1996). All experimental procedures and
protocols involving animals were approved by the insti-
tutional animal care committee of National Yang-Ming
University (Taipei, Taiwan) and in compliance with the
ARRIVE guidelines [19].
Mouse ischemic hindlimb model
Eight-week-old male wild-type mice and STZ-induced
diabetic mice received unilateral hindlimb ischemia sur-
gery by excising the right femoral artery as previously
described [20]. Local IFR therapy was given in STZ-
induced diabetic mice for 30 min twice per day for 2
weeks after the surgery, and wild-type and diabetic con-
trol mice were placed on a heating plate at 34°C for 30
min twice daily to avoid the thermal effect in this study.
Briefly, mice were anaesthetized by an intraperitoneal in-
jection of ketamine (100 mg/kg) and xylazine (10 mg/kg).
The depth of anesthesia was checked by ensuring that
noxious pinch stimulation (blunt forceps) of the hindpaw,
the forepaw, and the ear did not evoke any motor reflexes.
The proximal and distal portions of the femoral artery
were ligated. Hindlimb blood perfusion was measured
with a Laser Doppler perfusion imager system (Moor
Instruments Limited, Devon, UK) before and after the
surgery and followed weekly. To avoid the influence of
ambient light and temperature, the results were expressed
as the ratio of perfusion in the right (ischemic) versus left
(non-ischemic) limb.
Measurement of capillary density and oxidative stress in
the ischemic limb
At 4 weeks after surgery, the mice were euthanized via
intravenous ketamine injection. The femora were care-
fully removed, and the ischemic thigh muscles were em-
bedded in paraffin. Sections (5 μm) were de-paraffinized
and incubated with a rat monoclonal antibody against
murine CD31 (clone MEC13.1, BD PharMingen, San
Diego, CA). Antibody distribution was visualized by
using the avidin-biotin-complex technique and Vector
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lingame, CA), followed by counterstaining with
hematoxylin. Capillaries were identified by positive
staining for CD31. Ten different fields from each tissue
preparation were randomly selected, and visible capil-
laries were counted. Capillary density was expressed as
the number of capillaries per square millimeter. To
evaluate local oxidative stress levels in ischemic mus-
cles, an antibody against nitrotyrosine (Upstate, Lake
Placid, NY, USA) was used.Flow cytometry
To investigate the effects of IFR therapy on EPC
mobilization in response to tissue ischemia, the
fluorescence-activated cell sorting (FACS) Caliber flow
cytometer (Becton Dickinson, San Jose, CA, USA) was
used to assess EPC mobilization [18]. A volume of 100
μL peripheral blood was incubated with Fluorescein iso-
thiocyanate (FITC) anti-mouse Sca-1 (eBioscience, San
Diego, CA, USA), and phycoerythrin (PE) anti-mouse
Flk-1 (VEGFR-2, eBioscience) antibodies. Isotype-
identical antibodies served as controls (Becton Dickin-
son, Franklin Lakes, NJ, USA). After incubated for 30
minutes, cells were lysed (PharmLyse; BD Pharmingen),
washed with phosphate-buffered saline (PBS), and fixed
in 2% paraformaldehyde before analysis. Each analysis
included 100,000 events. Circulating EPCs were consid-
ered to be from the mononuclear cell population and
were gated with double positive for Sca-1 and Flk-1.Bone marrow transplantation model
Recipient wild-type mice at 8 weeks of age were lethally
irradiated with a total dose of 9.0 Gy [18,20]. eGFP
transgenic mice (FVB background) that ubiquitously
expressed enhanced GFP (Level Biotechnology Inc., Taipei,
Taiwan) were used as the donors. After being irradiated, a
recipient mouse received unfractionated bone marrow
cells (5×106) from an eGFP mouse by a tail vein injection.
Two months after the bone marrow transplantation, the
chimeric mice were induced diabetes by daily intravenous
injections of STZ as previously described. All mice
received a hindlimb ischemic surgery (n= 6 in each
group). Repopulation by eGFP-positive bone marrow cells
was 95%, as measured by flow cytometry. Two weeks after
the induction of hindlimb ischemic surgery in the bone
marrow-reconstituted and STZ-induced diabetic mice, tis-
sues were harvested for confocal immunofluorescent and
histological analysis. Bone marrow-derived EPCs were
stained with antibodies directed against eGFP (Chemicon)
and CD31 (BD PharMingen). EPC density was estimated
by counting eGFP+CD31+ double-positive cells (yellow
color) under high power field (HPF, ×100) in at least 6 dif-
ferent cross-sections from different animals.EPC transplantation in nude mice
Athymic nude mice at 6–8 weeks old were purchased
from the National Laboratory Animal Center, Taiwan.
Nude mice were then randomly assigned to 5 treatment
groups (n = 6 in each group) for intramuscular injection
of normal saline, healthy EPC, EPC treated with high
glucose for 4 days (EPC-HG), EPC treated with high glu-
cose and IFR for 30 mins (24 hours following by treat-
ment of EPCs in high-glucose conditions for 4 days)
(EPC-HG+ IFR), and EPC treated with high glucose
and transfected with eNOS siRNA (Santa Cruz-
Biotechnology Inc., CA, USA) and IFR for 30 mins
(EPC-HG+ eNOS siRNA+ IFR). EPCs were labeled with
fluorescent carbocyanine 1,1'-dioctadecyl-1 to 3,3,3',3'-
tetramethylindocarbocyanine perchlorate (DiI) dye
(Molecular Probes) [21]. Intramuscular injection was
performed 24 hours following unilateral hindlimb ische-
mia srugery. A total volume of 200 μl normal saline or
5 × 106 EPC were injected at 6 sites into the ischemic
hind limb distal to the arterial occlusion site. Three ven-
tral injections were placed in the upper limb in proxim-
ity to the adductor and semimembranosus muscles. The
remaining 3 injections were administered to the ventral
lower limb involving the gastrocnemius and flexor digi-
torum muscles. In order to achieve maximal experimen-
tal uniformity, transplanted EPCs were derived from the
same donors and used in parallel experiments.
Human EPC isolation and cultivation
Peripheral blood samples (20 ml) were obtained from
healthy young adult volunteers, and total mononuclear
cells (MNCs) were isolated by density gradient centrifu-
gation with Histopaque-1077 (1.077 g/ml, Sigma, St.
Louis, MO, USA) [20]. Briefly, MNCs (5×106) were pla-
ted in 2 ml endothelial growth medium (EGM-2 MV
Cambrex, East Rutherford, NJ, USA) with supplements
on fibronectin-coated 6-well plates. After 4 days of cul-
turing, the medium was changed and non-adherent cells
were removed; attached early EPCs appeared to be
elongated with spindle shapes. A certain number of
early EPCs were allowed to grow into ECFCs (endothe-
lial colonies forming cells), which emerged 2–4 weeks
after the start of the MNC culture. The ECFCs exhib-
ited a cobblestone morphology and monolayer growth
pattern typical of mature endothelial cells at confluence
[22]. ECFCs were collected and used for all the assays
in this study.
ECFC characterization
The ECFCs were characterized as adherent cells that
were positive for endothelial cell and haematopoietic
stem cell surface makers, as previously described [20].
The ECFCs were characterized by immunofluorescence
staining for the expression of VE-cadherin, platelet/
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and CD34, KDR, AC133 and eNOS (Santa Cruz). The
fluorescent images were recorded under a laser scanning
confocal microscope.
Measurement of reactive oxygen species (ROS)
production and measurement of nitrate levels
The effect of IFR therapy on ROS production in ECFCs
was determined by a fluorometric assay using 2',7'-
dichlorofluorescein diacetate (DCFH-DA, Molecular
Probes) as a probe for the presence of H2O2.
21 ECFCs
(104 cells/well) in 96-well plates was incubated in high
glucose medium for 4 days. After treatment of IFR radi-
ation, cells were incubated with 20 μmol/L DCFH-DA
for 45 minutes. The conditioned medium was measured
for nitrate level by Griess reagent [1% sulfanilamide and
0.1% N-(1-naphthyl) ethylenediamine in 2% phosphoric
acid]. The fluorescence intensity (relative fluorescence
units) was assessed at 485-nm excitation and 530-nm
emission using a fluorescence microplate reader.
EPC senescence assay
Cellular aging was determined with a Senescence Cell
Staining kit (Sigma). Briefly, after washing with PBS,
ECFCs were fixed for 6 minutes in 2% formaldehyde and
0.2% glutaraldehyde in PBS, and then incubated for 12
hours at 37°C without CO2 in fresh X-gal staining solu-
tion (1 mg/ml X-gal, 5 mM potassium ferricyanide, and
2 mM MgCl2; pH6). After staining, green-stained cells
and total cells were counted and the percentage of
β-galactosidase-positive cells was calculated [20].
EPC migration assay
The migratory function of ECFCs was evaluated by a
modified Boyden chamber assay (Transwell, Costar)
[20]. Briefly, isolated ECFCs were detached as described
above with trypsin/EDTA, and then 4×104 ECFCs were
placed in the upper chambers of 24-well transwell plates
with polycarbonate membranes (8-μm pores) that con-
tained serum-free endothelial growth medium. VEGF
(50 ng/ml) was added to medium placed in the lower
chambers. After incubation for 24 hours, the membrane
was washed briefly with PBS and fixed with 4% parafor-
maldehyde. The upper membrane side was wiped gently
with a cotton ball. The membrane was stained using
hematoxylin solution and carefully removed. The extent
of migration of ECFCs was evaluated by counting the
migrated cells in 6 random high-power (×100) micro-
scopic fields.
Western blotting analysis
ECFCs were lysed in buffer (62.5 mM Tris–HCl, 2%
SDS, 10% glycerol, 0.5 mM PMSF, 2 μg/ml aprotinin,
pepstatin and leupeptin), and the protein lysates weresubjected to SDS-PAGE, followed by electroblotting
onto a PVDF membrane [12]. Membranes were probed
with monoclonal antibodies against phosphorylated
endothelial NO synthase (p-eNOS), eNOS, Akt, p-Akt,
VEGF, p-ERK, p-38 MAPK, HO-1 (Cell Signaling) and
β-actin (Sigma). Bands were visualized by chemilumines-
cence detection reagents. Densitometric analysis used
ImageQuant (Promega) software.Statistical analysis
Results are given as means ± standard errors of the mean
(SEM). Statistical analysis was done by unpaired Stu-
dent’s t test or analysis of variance, followed by Scheffe’s
multiple-comparison post hoc test. Data were analyzed
using SPSS software (version 14; SPSS, Chicago, IL). A
p value of < 0.05 was considered statistically significant.Results
IFR therapy promotes blood flow recovery in diabetic
mice
Local IFR therapy was given in STZ-induced diabetic
mice for 30 min twice per day for 2 weeks after the sur-
gery, and wild-type and diabetic control mice were
placed on a heating plate at 34°C for 30 min twice daily
to avoid the thermal effect in this study. As shown in
Figure 1A, the STZ-induced diabetic mice without IFR
therapy showed delayed blood flow recovery after ische-
mia surgery compared with that in wild-type mice, as
determined by Laser Doppler imaging. Meanwhile, the
repeated IFR therapy significantly improved blood flow
recovery by 48% in STZ-induced diabetic mice (n = 6 per
group). However, the benefit of local IFR radiation was
significantly abolished after treatment with the eNOS inhibi-
tor NG-nitro-L-arginine methyl ester (L-NAME, 1 mg/ml in
drinking water). Consistent with the measurements by
Laser Doppler imaging, anti-CD31 immunostaining
revealed that repeated FIR radiation increased the number
of detectable capillaries in the ischemic muscle in STZ-
induced diabetic mice (control versus IFR: 38.8± 1.8 versus
48.7 ± 2.4/HPF, p= 0.008) (Figure 1B). However, adminis-
tration of L-NAME abolished the benefit of IFR radiation
(detectable capillaries, IFR versus IFR+L-NAME:
48.7 ± 2.4 versus 34.8± 1.7/HPF, p= 0.001).Effects of IFR radiation on oxidative stress in ischemic
limbs, EPC mobilization and homing process
To further evaluate the effect of IFR therapy on oxida-
tive stress on ischemic muscles, immunostaining against
nitrotyrosine was performed. As shown on Figure 2A,
assessed by nitrotyrosine staining, a significant reduction
of oxidative stress levels in ischemic muscles was noted
in diabetic mice that received IFR therapy.
Figure 1 Effects of far infrared (IFR) therapy on blood flow recovery and new vessels formation in STZ-induced diabetic mice.
(A) Representative results of laser Doppler measurements before operation and 4 weeks after hindlimb ischemia surgery in wild-type mice,
control (vehicle), IFR therapy, and IFR +NG-nitro-L-arginine methyl ester (L-NAME) mice. Color scale illustrates blood flow variations from minimal
(dark blue) to maximal (red) values. Arrows indicate ischemic (right) limb after hindlimb ischemia surgery. Doppler perfusion ratio (ischemic/non-
ischemic hind limb) over time in the different groups. Administration of L-NAME in drinking water abolished the beneficial effect of IFR therapy in
diabetic mice. (*p < 0.05 compared with DM-control; #p < 0.05 compared with DM-FIR; n = 6) (B) Mice were sacrificed 3 weeks after surgery and
capillaries in the ischemic muscles were visualized by anti-CD31 immunostaining. Results are mean± standard error of mean (SEM). (*p < 0.05
compared with DM-control; #p < 0.05 compared with DM-IFR; n = 6).
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EPC mobilization in response to tissue ischemia, levels
of Sca-1+/Flk-1+ cells in peripheral blood were deter-
mined by flow cytometry in STZ-induced diabetic mice
(n = 6 per group). EPCs mobilization was enhanced by
tissue ischemia in wild-type mice (baseline versus 2
days after operation: 0.60 ± 0.22 versus 1.34 ± 0.11%,
p = 0.016). However, impaired mobilization of EPCs in
peripheral blood after hindlimb ischemia was noted in
STZ-induced diabetic mice (baseline vs. 2 days after op-
eration: 0.45 ± 0.07 vs. 0.56 ± 0.09%, p = 0.374). As
shown in Figure 1C, administration of local IFR radi-
ation did not increase EPC mobilization in STZ-
induced diabetic mice (baseline versus 2 days afteroperation: 0.36 ± 0.12 versus 0.61 ± 0.10%, p = 0.140)
after hindlimb ischemia surgery.
To test the effect of repeated IFR radiation on bone
marrow-derived EPC homing and differentiation to
endothelial cells, STZ-induced diabetes was created in
FVB mice that received eGFP mouse bone marrow cells.
By immunofluorescence staining, STZ-induced diabetic
mice in the IFR group had more GFP+/CD31+ double-
positive cells in ischemic muscle than those in control
group (control versus IFR: 11.2 ± 1.1 versus 18.8 ± 2.0/
HPF, p = 0.007, n = 6; Figure 2). In addition, administra-
tion of the eNOS inhibitor significantly diminished the
effect of IFR radiation on EPC homing. These results
suggested that repeated IFR therapy did not promote
Figure 2 Effects of IFR radiation on oxidative stress, EPC mobilization after hindlimb ischemia and tissue homing in STZ-induced
diabetic mice. (A) Effect of IFR on oxidative stress in ischemic muscles of STZ-induced diabetic mice. Nitrotyrosine (n = 4 per group)
immunostaining of ischemic muscles extracted on day 21 in control (vehicle), and in mice that had received IFR radiation. (*p < 0.05 compared
with DM-control) (B) EPCs (defined as Sca-1+/Flk-1+ cells) mobilization after tissue ischemia was determined by flow cytometry in STZ-induced
diabetic mice given the vehicle, IFR or IFR + L-NAME. (*p < 0.05 compared with WT-baseline; n = 6 per group) (C) STZ-induced diabetes was
created in FVB mice that received eGFP mouse bone marrow cells. By immunofluorescence staining, STZ-induced diabetic mice in IFR group had
more GFP+/CD31+ double-positive cells in ischemic muscle than those in the vehicle group. (*p < 0.05 compared with DM-control; #p < 0.05
compared with DM-FIR; n = 6).
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circulating EPCs’ homing to ischemic tissue.
Characterization of Human ECFCs
ECFCs were isolated from peripheral blood MNCs of
healthy young adult volunteers as previously described
[22]. The peripheral blood MNCs that initially seeded
on fibronectin-coated wells were in round shape
(Figure 3A). After the medium was changed on day 4,
attached MNCs appeared to be elongated with a spin-
dle shape (Figure 3B). ECFCs with a cobblestone-like
morphology similar to mature endothelial cells were
grown to confluence (Figure 3C). ECFCs characterization
was performed by immunohistochemical staining, and
most of the cells expressed mature endothelial markers,
VE-cadherin, PECAM-1 (CD31), CD34, KDR, AC133
and eNOS (Figure 3), which are considered as critical
markers of late EPCs.IFR decreases reactive oxidative stress and enhances EPC
proliferation, NO production in high glucose conditions
High glucose markedly increased H2O2 production
determined by the relative DCFH-DA fluorescent inten-
sity, and administration of IFR radiation (10–60 mins)
significantly suppressed the high glucose-induced ROS
index in cultures of ECFCs (Figure 4A).
As shown in Figure 4B, incubation with high glucose
medium for 4 days significantly reduced EPC prolifera-
tion (control versus high glucose, 100 ± 2 versus 88 ± 5,
p = 0.026). However, administration of IFR radiation for
40 min following by treatment of EPCs in high-glucose
conditions significantly reversed the reduction in EPC
proliferation in response to high glucose (high glucose
versus high glucose + IFR 40 mins, 88 ± 5 versus 109 ± 2,
p = 0.006).
High glucose impairs eNOS activation and reduces
NO bioavailability in cultured EPCs [7]. We therefore
Figure 3 Morphology and characterization of human endothelial progenitor cells (EPCs) from peripheral blood. (A) Peripheral blood
mononuclear cells (MNCs) were plated on a fibronectin-coated culture dish on the first day. (B) Four days after plating, adherent early EPCs with
a spindle shape were shown. (C) Three weeks after plating, ECFCs with a cobblestone-like morphology were selected, reseeded, and grown to
confluence. (D-I) ECFC characterization was performed by immunohistochemical staining. Most of the EPC expressed endothelial and
hematopoietic stem cell markers, VE-cadherin, PECAM-1 (CD31), CD34, KDR, AC133, and eNOS, which are considered critical markers of EPCs. Cells
were counterstained with 4',6-diamidino-2-phenylindole (DAPI) for the nuclei (blue).
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treated EPCs to determine whether IFR could recover
impaired NO production in EPCs. After 4 days of incu-
bation in 25 mM high glucose medium, the NO produc-
tion in cultured medium was significantly decreased
(Figure 4C). However, administration of IFR radiation
for 30 mins following by treatment of EPCs in high-
glucose conditions can significantly upregulate high
glucose-impaired No production.
IFR radiation upregulates phosphorylation of eNOS, and
enhances VEGF in high glucose conditions
We investigated the effects of IFR radiation on high
glucose-treated EPCs to determine whether IFR therapy
could recover impaired eNOS activation in EPCs. Ad-
ministration of IFR radiation on cultured ECFCs for 10,
30, and 40 min followed by treatment of EPCs in high
glucose conditions significantly upregulated high
glucose-impaired eNOS production and eNOS activity
(p-eNOS/total eNOS). Treatment of IFR therapy for 30,
40 and 60 min also upregulated Akt activation (p-Akt/
total Akt). In addition, administration IFR radiation also
promoted VEGF production, p-ERK, and p-38 MAPK inhigh glucose conditions, but not HO-1 (Figure 5). These
findings suggested that treatment with IFR radiation
may enhance activities of eNOS, Akt, p-ERK, p-38
MAPK and VEGF production in EPCs in response to
high glucose stimulation.
IFR improves high glucose-suppressed EPC functions and
senescence in vitro
To investigate the effects of IFR radiation on EPCs, we
used both scratch test and modified Boyden chamber
assay to assess the migratory function of EPCs in high
glucose conditions. Compared with the control group,
incubation of EPCs with high glucose (4 days) signifi-
cantly decreased EPC migration (100 ± 9 versus
63 ± 11/HPF, p = 0.031). However, treatment with IFR
radiation for 30 minutes significantly recovered high
glucose-suppressed late EPC migratory function (high
glucose versus high glucose + IFR, 63 ± 11 versus
174 ± 10 cells/HPF, p = 0.005; Figure 6A). Similar find-
ings were observed by modified Boyden chamber assay
(Figure 6B).
After 4 days of culturing, the capacity for tube forma-
tion of EPCs on ECMatrix gel was significantly reduced
Figure 4 IFR therapy decreased reactive oxidative stress,
recovered EPC proliferation, and increased NO production in
high-glucose conditions. (A) High glucose markedly increased
H2O2 production determined by the relative DCFH-DA fluorescent
intensity, and the administration of IFR therapy suppressed high
glucose-induced reactive oxidative stress (ROS) index in EPCs culture.
(*p < 0.05 compared with control - 0 min; #p < 0.05 compared with
high glucose - 0 min) (B) The effect of IFR radiation on EPCs
proliferation was analyzed by MTT assay. (*p < 0.05 compared with
control - 0 min; #p < 0.05 compared with high glucose - 0 min) (C)
Nitrate production (as NO content) in culture medium was
measured by Griess reagent. High glucose-suppressed NO
production in cultured late EPC s. After 4 days of incubation, IFR
radiation increased NO production with or with high glucose
conditions. (*p < 0.05 compared with control - 0 min; #p < 0.05
compared with high glucose - 0 min; **p < 0.05 compared with
control – 0 min; n = 4 for each experiment).
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trol group, whereas treatment with IFR radiation for 30
mins followed by treatment of EPCs in high-glucose
conditions ameliorated this high glucose suppressed-
tube formation by EPCs (100 ± 15 vs. 195 ± 3 cells/HPF,
p = 0.003; Figure 6C).
Compared with the control group, incubation of EPCs
with high glucose significantly increased the percentage
of senescence-associated ß-galactosidase-positive EPCs
(100 ± 6 versus 119 ± 5%, p = 0.032). Administration of
IFR radiation (30 mins) followed by treatment of EPCsin high-glucose medium significantly attenuated the per-
centage of senescence-associated ß-galactosidase-positive
EPCs (high glucose versus high glucose + IFR, 119± 5 ver-
sus 87± 9%, p= 0.013; Figure 6D).
EPC treated IFR radiation transplantation improves
hindlimb perfusion
In the animals receiving normal saline, blood flow
remained constant throughout the study, around 42% of
that measured in the non-ischemic limb (42 ± 8%, four
weeks after operation). In contrast, the mice trans-
planted with EPC and EPC received IFR therapy (30
mins) in high glucose medium (EPC-HG+ IFR), but not
EPC in high glucose medium without IFR therapy (EPC-
HG) and EPC treated with high glucose and IFR and
eNOS siRNA (EPC-HG+ eNOS siRNA+ IFR) already
showed a significant improvement in blood flow by three
weeks after EPCs implantation (both p < 0.05; Figure 7).
Consistent with the measurements by Laser Doppler im-
aging, anti-CD31 immunostaining revealed that trans-
plantation of EPC and EPC treated with IFR in high
glucose conditions significantly increased the number of
detectable capillaries in the ischemic muscle than mice
received normal saline (both p < 0.05 compared to nor-
mal saline). However, treatment with eNOS siRNA abol-
ished the benefit of IFR radiation in high glucose
medium (IFR versus IFR + eNOS siRNA: 38.7 ± 4.7 ver-
sus 21.3 ± 3.7/HPF, p = 0.015, n = 6 per group).
Discussion
This study first to show a favorable effect of IFR radi-
ation on ischemia-induced neovascularization in diabetic
mice. Repeated IFR radiation enhanced blood flow re-
covery and new vessel formation in ischemic hindlimbs,
and the beneficial effect may be derived from enhance-
ment of EPC homing process by reduction of oxidative
stress in ischemic tissue rather than promotion of EPC
Figure 5 Effects of IFR radiation on eNOS, Akt, p-ERK, p-38 MAPK, VEGF and HO-1 production in cultured EPCs. Administration of IFR
radiation on cultured ECFCs for 10, 30, and 40 min followed by treatment of EPCs in high-glucose conditions significantly upregulated high
glucose-impaired eNOS production and eNOS activity (p-eNOS/total eNOS). Treatment of IFR therapy for 30, 40 and 60 min also upregulated Akt
activation (p-Akt/total Akt). In addition, administration IFR radiation also promoted VEGF production, p-ERK, and p-38 MAPK in high glucose
conditions, but not HO-1. Each bar graph shows the summarized data from four separate experiments by densitometry after normalization. Data
are means ± SEM; n = 4 in each experiment. (*p < 0.05 compared with control; #p< 0.05 compared with HG group.).
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ameliorate high glucose-induced oxidative stress, attenu-
ate cellular senescence and improve EPC functions. Mice
received EPC treated with IFR radiation showed a sig-
nificant improvement in blood flow recovery after tissue
ischemia in comparison to those received normal saline.
Given the evidence mentioned above, our findings indi-
cated the direct beneficial effects of IFR radiation on
blood flow recovery after tissue ischemia, and IFR radi-
ation counteracts the detrimental effect of a diabetic en-
vironment on improvement of EPC functions, which
may provide some novel rationales for its potential clin-
ical impact on vascular protection.Improved neovascularization in response to tissue is-
chemia is an important therapeutic strategy to reduce
organ damage. Convincing evidence suggests that neo-
vascularization in adults is not solely the result of the
proliferation of endothelial cells (angiogenesis) but also
involves circulating EPCs in the process of vasculogen-
esis [7]. These circulating EPCs are derived from bone
marrow and are mobilized endogenously, triggered by
tissue ischemia, or exogenously by cytokine stimula-
tion, such as VEGF and stromal cell-derived factor-1
(SDF-1) [23].
However, patients with diabetes or cardiovascular risk
factors were shown to have decreased numbers and
Figure 6 Effects of IFR therapy on EPC migration, tube formation, and senescence in vitro. (A,B) Scratch test and modified Boyden
chamber assay were used to assess the migratory function of ECFCs in high glucose conditions. Boyden chamber assay using VEGF as a
chemoattracting factor was used to evaluate the effects of IFR radiation on EPC migration. (C) An in vitro angiogenesis assay for late ECFCs used
ECMatrix gel. Representative photos for in vitro angiogenesis are shown. Cells were stained with crystal violet, and the averages of the total area
of complete tubes formed by cells were compared by using computer software. (D) To determine the onset of cellular aging, acidic ß-
galactosidase was used as a biochemical marker for acidification, typical for ECFCs senescence. Data are means ± SEM; n = 4 in each experiment.
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indicated that advanced glycation end products (AGEs)
promoted EPC apoptosis [26], and long-term exposure
to high glucose may enhance cellular senescence and re-
duce cell numbers and functional competencies of EPCs
via NO-related mechanisms [10]. Mobilization and dif-
ferentiation of EPCs are modified by NO, and bone
marrow-expressed eNOS is essential for the mobilization
of stem and progenitor cells [27]. In addition, endogenous
NOS inhibitors, such as asymmetric dimethylarginine
(ADMA), were shown to suppress EPC differentiation
and function, and contributed to impaired endothelial
function [28]. These findings provide a rationale
for potential therapeutic targets for hyperglycemia-suppressed EPC functions, and diabetes-related vascular
complications.
Diabetic patients frequently suffer from micro- or
macrovascular abnormalities, including retinopathy,
nephropathy, neuropathy and accelerated atheroscler-
osis. It is evident that decreased bioavailability of NO
produced from eNOS plays a crucial role in the develop-
ment and progression of atherosclerosis. Under various
pathological conditions such as type 2 diabetes eNOS
may become dysfunctional or its expression may be
decreased. Endothelial dysfunction is associated with
childhood obesity and is closely linked to the amount
and function of EPCs, and a combined after-school exer-
cise program was shown to increase circulating EPC
Figure 7 IFR treated-EPC transplantation improved blood perfusion in the ischemic hindlimb. (A) Representative images of hindlimb
blood flow measured by laser Doppler and quantitative analysis of blood flow expressed as perfusion ratio of the ischemic to the contralateral
(non-operated) hindlimb immediately after hindlimb ischemia surgery and 3 weeks after intramuscular injection of normal saline, EPC-treated
with high glucose (EPC-HG), EPC-treated with high glucose and FIR therapy (EPC-HG+ IFR), or EPC treated with high glucose and IFR and eNOS
siRNA (EPC-HG+ eNOS siRNA+ IFR). (*p < 0.05 compared with control; #p < 0.05 compared with EPC-HG+ IFR; n = 6).
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over, enhancement of oxidative stress by tissue ischemia
may downregulate NO bioavailability because free radi-
cals can directly inactivate NO [30]. Inadequate angio-
genic response to ischemia in the ischemic limbs or
myocardium of diabetic patients could result in poor
collateral formation and severe organ damage.
IFR radiation is an invisible electromagnetic wave with
a characteristic wavelength between 5.6 and 1000 μm
that can be perceived as heat by thermo-receptors in
skin [11,12]. The technology of IFR has been applied
widely in a variety of fields. The thermal effect of IFR
results in vasodilation and increasing tissue blood flow.
Local IFR therapy may allow multiple energy transfer as
deep as 2 to 3 cm into subcutaneous tissue without irri-
tating or overheating the skin like unfiltered heat radi-
ation [31]. The skin temperature steadily increased to a
plateau at approximately 38 to 39°C during the treat-
ment of FIR for 30 to 60 min as long as the distance be-
tween the ceramic plate and the skin was >20 cm [16].
Therefore, infrared therapy can be free of the disadvan-
tages or adverse effects of thermal therapy. In this study,
wild-type and diabetic control mice were placed on a
heating plate at 34°C for 30 min twice daily to avoid the
thermal effect between groups. The rectal temperaturewas also assessed in these mice, and showed no
temperature elevation in mice received IFR therapy
compared to those without IFR radiation.
In addition to the thermal effect, increasing evidence
suggests nonthermal effects of IFR therapy exert benefi-
cial effects in the cardiovascular system through NO-
related pathway [31,32]. In animal studies, Akasaki and
colleagues demonstrated that repeated IFR therapy could
upregulate eNOS expression and augment angiogenesis
in an apolipoprotein E–deficient mouse model of unilat-
eral hindlimb ischemia [16]. In human study, Imamura
et al. showed that two weeks of repeated sauna therapy
significantly improved vascular endothelial function,
resulting in an increase of flow-mediated, endothelium-
dependent dilation of the brachial artery from 4 to 5.8%
in patients with coronary risk factors [14]. These find-
ings suggested nonthermal effect of IFR may derive from
upregulation of eNOS activity and enhancement of NO
bioavailability. In the study, we demonstrated that
repeated IFR therapy could activate eNOS and Akt, and
upregulate the migration and tube formation capacities
of ECFCs. Akt is downstream from PI 3-kinase and is
capable of directly phosphorylating eNOS at Ser1179,
resulting in its activation. Recent evidence also indicated
that p-38 MAPK plays a key role in downregulating
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http://www.cardiab.com/content/11/1/99EPCs by hyperglycemia in diabetic patients [33]. EPCs
exposed to IFR upregulated expression of p-38 MAPK
and p-ERK. These findings are in line with recent study
showing that IFR radiation significantly promoted angio-
genesis by a MAP kinase dependent pathway on mature
endothelial cells. Mice received EPC treated with IFR ra-
diation in high glucose conditions showed a significant
improvement in blood flow recovery after tissue ische-
mia compared with those received normal saline. These
beneficial effects may provide some novel rationale for
the vascular protective properties of IFR therapy in dia-
betic patients with critical limb ischemia or clinical im-
plication to treat dysfunctional EPCs before cell therapy.
Conclusions
This study provides the first evidence that the adminis-
tration of IFR therapy promoted collateral flow recovery
and new vessel formation in STZ-induced diabetic mice.
These beneficial effects may derive from enhancement
of EPC functions and homing process, which provide
some novel rationale for the vascular protective proper-
ties of IFR therapy in diabetic patients with critical limb
ischemia or further clinical implication in cell therapy.
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